National Academies Press: OpenBook
« Previous: Appendix B: Open Session Agenda
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×

C

Literature Searches

Literature searches were performed in Medline, Embase, PubMed, and Scopus in February 2021. They were not restricted to a specific time period and are presented in the following tables.

Database: Medline

Search Date: 02/25/21

Search No. Syntax Results
1 Riboflavin/ or Flavin mononucleotide/ or Flavin adenine dinucleotide/ 14,464
2 (riboflavin or Flavin mononucleotide or Flavin adenine dinucleotide or FMN).ti,ab,kw,kf. 14,394
3 ("FMN" OR "FAD").mp. 11,579
4 1 OR 2 OR 3 25,996
5 Erythrocytes/ AND Glutathione reductase/ 1,141
6 Erythrocytes/ and Flavins/ 29
7 (erythrocyte glutathione reductase* or red blood cell glutathione reductase* or RBC glutathione reductase* or erythrocyte Flavin* or red blood cell Flavin* or RBC Flavin* or EGRAC* or E-GRAC* or E grac*).ti,ab,kw,kf. 655
8 5 or 6 or 7 1,645
9 4 or 8 27,231
10 Anemia/ or anemia, hemolytic/ or blood pressure/ or cardiovascular diseases/ or dermatitis, seborrheic/ or flavins/ or glossitis/ or glutathione reductase/ or growth disorders/ or hemoglobins/ or hypertension/ or Leukemia/ or Lymphoma/ or Melanoma/ or mononeuropathies/ or neoplasms/ or Nervous system diseases/ or nervous system diseases/ or nervous system malformations/ or No-Observed-Adverse-Effect Level/ or peripheral nervous system diseases/ or Pheochromocytoma/ or polyneuropathies/ or Pre-eclampsia/ or Retinoblastoma/ or Sarcoma/ or skin diseases/ or stomatitis/ or vascular stiffness/ or vitamin b 6/ 1,527,203
11 (Anemia or blood pressure or cancer* or cardio vascular or cardiovascular or cardio-vascular or Cheilosis or Dermatitis or E GRAC or EGRAC or EGRAC or Glossitis or growth disorder* or growth retardation or 4,519,018
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Haemoglobin* or Hemoglobin* or hyper tens* or hypertens* or hyper-tens* or leukemia* or lymphoma* or melanoma* or microcytic anemia* or neoplas* or nervous system or neurologic* or neuropath* or Pheochromocytoma* or pre eclampsia or preeclampsia or pre-eclampsia or Pyridox* or retinoblastoma* or sarcoma* or Seborrheic or Stomatitis or tumor* or Vit B 6 or Vit B6 or Vit B-6 or Vitamin B 6 or Vitamin B-6).ti,ab,kw,kf.
12 Long term adverse effects/ 638
13 (Toxicity or high dose* or adverse event* or adverse effect* or dose-response* or LOAEL or NOAEL).ti,ab,kw,kf. 765,237
14 Biological availability/ 40,807
15 Deficiency.fs. 167,298
16 (Bioavailabilit* or Bio-availabilit* or Deficien*).ti,ab,kw,kf. 531,186
17 10 or 11 or 12 or 13 or 14 or 15 or 16 5,874,324
18 9 and 17 8,024
19 Diet/ or dietary supplements/ or food/ 244,052
20 (diet* or food*).ti,ab,kw,kf. 839,505
21 19 or 20 912,505
22 18 and 21 1,641
23 (abstracts or academic dissertation or comment or editorial or letter or meeting abstract or meta analysis or review or systematic review).pt. 4,343,870
24 22 not 23 1,439
25 24 not (Animals/ not (Animals/ and Humans/)) 1,022
26 limit 25 to English language 930

Database: Embase

Search Date: 02/25/21

Search No. Syntax Results
1 Riboflavin/ or Flavin mononucleotide/ or Flavin adenine dinucleotide/ 21,543
2 (riboflavin or Flavin mononucleotide or Flavin adenine dinucleotide or FMN).ti,ab,kw. 15,583
3 ("FMN" OR "FAD").mp. 13,294
4 1 OR 2 OR 3 32,384
5 Erythrocytes/ AND Glutathione reductase/ 906
6 Erythrocytes/ and Flavins/ 7
7 (erythrocyte glutathione reductase* or red blood cell glutathione reductase* or RBC glutathione reductase* or erythrocyte Flavin* or red blood cell Flavin* or RBC Flavin* or EGRAC* or E-GRAC* or E grac*).ti,ab,kw. 680
8 5 or 6 or 7 1,461
9 4 or 8 33,533
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
10 Anemia/ or anemia, hemolytic/ or blood pressure/ or cardiovascular diseases/ or dermatitis, seborrheic/ or flavins/ or glossitis/ or glutathione reductase/ or growth disorders/ or hemoglobins/ or hypertension/ or Leukemia/ or Lymphoma/ or Melanoma/ or mononeuropathies/ or neoplasms/ or Nervous system diseases/ or nervous system diseases/ or nervous system malformations/ or No-Observed-Adverse-Effect Level/ or peripheral nervous system diseases/ or Pheochromocytoma/ or polyneuropathies/ or Pre-eclampsia/ or Retinoblastoma/ or Sarcoma/ or skin diseases/ or stomatitis/ or vascular stiffness/ or vitamin b 6/ 1,574,674
11 (Anemia or blood pressure or cancer* or cardio vascular or cardiovascular or cardio-vascular or Cheilosis or Dermatitis or E GRAC or EGRAC or EGRAC or Glossitis or growth disorder* or growth retardation or Haemoglobin* or Hemoglobin* or hyper tens* or hypertens* or hyper-tens* or leukemia* or lymphoma* or melanoma* or microcytic anemia* or neoplas* or nervous system or neurologic* or neuropath* or Pheochromocytoma* or pre eclampsia or preeclampsia or pre-eclampsia or Pyridox* or retinoblastoma* or sarcoma* or Seborrheic or Stomatitis or tumor* or Vit B 6 or Vit B6 or Vit B-6 or Vitamin B 6 or Vitamin B-6).ti,ab,kw. 6,699,607
12 Long term adverse effects/ 156,208
13 (Toxicity or high dose* or adverse event* or adverse effect* or dose-response* or LOAEL or NOAEL).ti,ab,kw. 1,254,488
14 Biological availability/ 46,687
15 (Bioavailabilit* or Bio-availabilit* or Deficien*).ti,ab,kw. 748,108
16 10 or 11 or 12 or 13 or 14 or 15 8,444,217
17 9 and 16 11,888
18 Diet/ or dietary supplements/ or food/ 281,070
19 (diet* or food*).ti,ab,kw. 1,172,330
20 18 or 19 1,216,750
21 17 and 20 3,508
22 (abstracts or academic dissertation or comment or editorial or letter or meeting abstract or meta analysis or review or systematic review).pt. 4,503,857
23 21 not 22 2,955
24 23 not ((exp animal/ or nonhuman/) not exp human/) 2,375
25 limit 24 to English language 2,231
26 limit 25 to (pubmed-not-medline or pubmed/medline) 182
27 25 not 26 2,049

Database: PubMed

Search Date: 02/25/21

Search No. Syntax Results
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
1 riboflavin[MeSH Terms] OR flavin mononucleotide[MeSH Terms] OR Flavin adenine dinucleotide[MeSH Terms] 14,478
2 riboflavin[Title/Abstract] OR "Flavin mononucleotide"[Title/Abstract] OR "Flavin adenine dinucleotide"[Title/Abstract] OR "FMN"[Title/Abstract] OR "FAD"[Title/Abstract] 23,150
3 #1 or #2 27,742
4 Erythrocytes[MeSH Terms] AND Glutathione reductase[MeSH Terms] 1,194
5 Erythrocytes[MeSH Terms] AND flavins[MeSH Terms] 433
6 "erythrocyte glutathione reductase*"[Title/Abstract] or "red blood cell glutathione reductase*"[Title/Abstract] or "RBC glutathione reductase*"[Title/Abstract] or "erythrocyte Flavin*"[Title/Abstract] or "red blood cell Flavin*"[Title/Abstract] or "RBC Flavin*"[Title/Abstract] or "EGRAC*"[Title/Abstract] or "E-GRAC*"[Title/Abstract] or "E grac*"[Title/Abstract] 713
7 #4 or #5 or #6 1,925
8 #3 or #7 29,076
9 Anemia[MeSH Terms] or anemia, hemolytic[MeSH Terms] or blood pressure[MeSH Terms] or cardiovascular diseases[MeSH Terms] or dermatitis, seborrheic[MeSH Terms] or flavins[MeSH Terms] or glossitis[MeSH Terms] or glutathione reductase[MeSH Terms] or growth disorders[MeSH Terms] or hemoglobins[MeSH Terms] or hypertension[MeSH Terms] or Leukemia[MeSH Terms] or Lymphoma[MeSH Terms] or Melanoma[MeSH Terms] or mononeuropathies[MeSH Terms] or neoplasms[MeSH Terms] or Nervous system diseases[MeSH Terms] or nervous system diseases[MeSH Terms] or nervous system malformations[MeSH Terms] or No-Observed-Adverse-Effect Level[MeSH Terms] or peripheral nervous system diseases[MeSH Terms] or Pheochromocytoma[MeSH Terms] or polyneuropathies[MeSH Terms] or Pre-eclampsia[MeSH Terms] or Retinoblastoma[MeSH Terms] or Sarcoma[MeSH Terms] or skin diseases[MeSH Terms] or stomatitis[MeSH Terms] or vascular stiffness[MeSH Terms] or vitamin b 6[MeSH Terms] 8,352,121
10 Anemia[Title/Abstract] or "blood pressure"[Title/Abstract] or cancer*[Title/Abstract] or "cardio vascular"[Title/Abstract] or cardiovascular[Title/Abstract] or "cardio-vascular"[Title/Abstract] or Cheilosis[Title/Abstract] or Dermatitis[Title/Abstract] or "E GRAC"[Title/Abstract] or "EGRAC"[Title/Abstract] or "EGRAC"[Title/Abstract] or Glossitis[Title/Abstract] or "growth disorder*"[Title/Abstract] or "growth retardation"[Title/Abstract] or Haemoglobin*[Title/Abstract] or Hemoglobin*[Title/Abstract] or "hyper tens*"[Title/Abstract] or hypertens*[Title/Abstract] or "hypertens*"[Title/Abstract] or leukemia*[Title/Abstract] or lymphoma*[Title/Abstract] or melanoma*[Title/Abstract] or "microcytic anemia*"[Title/Abstract] or neoplas*[Title/Abstract] or "nervous system"[Title/Abstract] or neurologic*[Title/Abstract] or 5,171,542
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
neuropath*[Title/Abstract] or Pheochromocytoma*[Title/Abstract] or "pre eclampsia"[Title/Abstract] or preeclampsia[Title/Abstract] or "preeclampsia"[Title/Abstract] or Pyridox*[Title/Abstract] or retinoblastoma*[Title/Abstract] or sarcoma*[Title/Abstract] or Seborrheic[Title/Abstract] or Stomatitis[Title/Abstract] or tumor*[Title/Abstract] or "Vit B 6"[Title/Abstract] or "Vit B6"[Title/Abstract] or "Vit B-6"[Title/Abstract] or "Vitamin B 6"[Title/Abstract] or "Vitamin B-6"[Title/Abstract]
11 Long term adverse effects[MeSH terms] 638
12 Toxicity[Title/Abstract] or "high dose*"[Title/Abstract] or "adverse event*"[Title/Abstract] or "adverse effect*"[Title/Abstract] or "dose-response*" [Title/Abstract] or "LOAEL"[Title/Abstract] or "NOAEL"[Title/Abstract] 882,680
13 Biological availability[MeSH Terms] 40,843
14 Bioavailabilit*[Title/Abstract] or "Bio-availabilit*"[Title/Abstract] or Deficien*[Title/Abstract] 5,96,012
15 #9 or #10 or #11 or #12 or #13 or #14 10,739,352
16 #8 and #15 20,260
17 Diet[MeSH Terms] or dietary supplements[MeSH Terms] or food[MeSH Terms] 827,411
18 diet*[Title/Abstract] or food*[Title/Abstract] 984,410
19 #17 or #18 1,440,705
20 #16 and #19 3,713
21 comment [Publication Type] or editorial [Publication Type] or letter [Publication Type] or meta analysis [Publication Type] or review [Publication Type] or systematic review [Publication Type] 4,761,910
22 #20 not #21 3,356
23 #22 NOT ("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh])) 2,048
24 #24 and (pubmednotmedline[sb]) 86
Filter: English[Language]

Database: Scopus

Search Date: 02/26/21

( ( ( TITLE-ABS-KEY ( ( RIBOFLAVIN OR "FLAVIN MONONUCLEOTIDE" OR "FLAVIN ADENINE DINUCLEOTIDE" OR "FMN" OR "FAD" OR "ERYTHROCYTE GLUTATHIONE REDUCTASE*" OR "RED BLOOD CELL GLUTATHIONE REDUCTASE*" OR "RBC GLUTATHIONE REDUCTASE*" OR "ERYTHROCYTE FLAVIN*" OR "RED BLOOD CELL FLAVIN*" OR "RBC FLAVIN*" OR "EGRAC*" OR "E-GRAC*" OR "E GRAC*" ) AND ( ANEMIA OR "BLOOD PRESSURE" OR CANCER* OR "CARDIO VASCULAR" OR CARDIOVASCULAR OR "CARDIO-VASCULAR" OR CHEILOSIS OR DERMATITIS OR "E GRAC" OR "EGRAC" OR "E-GRAC" OR GLOSSITIS OR "GROWTH DISORDER*" OR "GROWTH RETARDATION" OR HAEMOGLOBIN* OR

Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×

HEMOGLOBIN* OR "HYPER TENS*" OR HYPERTENS* OR "HYPER-TENS*" OR LEUKEMIA* OR LYMPHOMA* OR MELANOMA* OR "MICROCYTIC ANEMIA*" OR NEOPLAS* OR "NERVOUS SYSTEM" OR NEUROLOGIC* OR NEUROPATH* OR PHEOCHROMOCYTOMA* OR "PRE ECLAMPSIA" OR PREECLAMPSIA OR "PREECLAMPSIA" OR PYRIDOX* OR RETINOBLASTOMA* OR SARCOMA* OR SEBORRHEIC OR STOMATITIS OR TUMOR* OR "VIT B 6" OR "VIT B6" OR "VIT B-6" OR "VITAMIN B 6" OR "VITAMIN B-6" OR TOXICITY OR "HIGH DOSE*" OR "ADVERSE EVENT*" OR "ADVERSE EFFECT*" OR "DOSE-RESPONSE*" OR "LOAEL" OR "NOAEL" OR BIOAVAILABILIT* OR "BIO-AVAILABILIT*" OR DEFICIEN* ) ) ) AND ( TITLE-ABS-KEY ( DIET* OR FOOD* ) ) ) AND ( INDEXTERMS ( HUMAN* ) OR TITLE-ABS-KEY ( HUMAN* ) ) ) AND NOT ( INDEX ( MEDLINE ) ) AND ( EXCLUDE ( DOCTYPE , "RE" ) OR EXCLUDE ( DOCTYPE , "LE" ) OR EXCLUDE ( DOCTYPE , "ED" ) OR EXCLUDE ( DOCTYPE , "CH" ) ) AND ( LIMIT-TO ( LANGUAGE , "ENGLISH" ) )

Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 53
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 54
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 55
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 56
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 57
Suggested Citation:"Appendix C: Literature Searches." National Academies of Sciences, Engineering, and Medicine. 2021. Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review. Washington, DC: The National Academies Press. doi: 10.17226/26188.
×
Page 58
Next: Appendix D: Committee Member Biographies »
Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review Get This Book
×
Buy Paperback | $40.00 Buy Ebook | $32.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The Dietary Reference Intakes (DRIs) are a set of evidence-based nutrient reference values for intakes that include the full range of age, gender, and life stage groups in the US and Canada. At the request of the U.S. Department of Agriculture, Agricultural Research Service and the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, the National Academies of Science, Engineering, and Medicine convened an ad hoc committee to carry out a literature search and evidence scan of the peer-reviewed published literature on indicators of nutritional requirements, toxicity, and chronic disease risk reduction for riboflavin.

Scanning for New Evidence on Riboflavin to Support a Dietary Reference Intake Review builds on the methodology for evidence scanning nutrients (which have existing DRIs) to determine whether there is new and relevant knowledge available that may merit a formal reexamination of DRIs for riboflavin. This report offers comments on the methodological approach to the evidence scan and discusses its findings and interpretation of the process to provide the study sponsors with a greater context to support their interpretation and application of the reported results.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!